What is the recommended initial dose and titration schedule of losartan for an adult with hypertension, including adjustments for elderly or frail patients, moderate (creatinine clearance 30–60 mL/min) or severe renal impairment, heart failure, and diabetic kidney disease?

Losartan Dosing for Hypertension and Special Populations

Standard Adult Dosing for Hypertension

Initiate losartan at 50 mg once daily and titrate to 100 mg once daily after 2–4 weeks if blood pressure remains ≥140/90 mmHg; 100 mg once daily is the maximum recommended dose for hypertension. 1

• The starting dose of 50 mg once daily can be taken at any time of day without regard to food, with peak plasma concentrations reached 1–2 hours after administration. 2
• If blood pressure is not controlled on 100 mg daily after 4–8 weeks, add hydrochlorothiazide 12.5–25 mg daily rather than exceeding the maximum losartan dose. 1
• Losartan may be administered once daily or divided into twice-daily dosing (e.g., 50 mg every 12 hours for a total of 100 mg/day), though once-daily dosing is more commonly recommended. 1
• Blood pressure should be reassessed every 2–4 weeks during titration, aiming for a target of <130/80 mmHg (minimum <140/90 mmHg) within 3 months of therapy initiation. 1, 3

Elderly or Frail Patients (≥75 Years)

No initial dose adjustment is required in elderly patients, but titration should proceed more gradually with close monitoring for hypotension and orthostatic changes. 1, 4

• Initiate losartan at 50 mg once daily in patients ≥75 years, with dose increases every 2–4 weeks rather than weekly to reduce the risk of hypotension and renal insufficiency. 1
• Measure blood pressure in both sitting and standing positions (after 5 minutes seated, then at 1 minute and 3 minutes after standing) before initiating or intensifying therapy to detect orthostatic hypotension. 1
• Elderly patients tolerate losartan well, with treatment-related adverse events (19–27%) similar to other antihypertensives and better than captopril (11% vs 16%). 4
• Continue lifelong antihypertensive treatment beyond age 85 when well tolerated, because discontinuation raises cardiovascular risk. 1

Renal Impairment

Moderate Renal Impairment (CrCl 30–60 mL/min)

Losartan 50–100 mg daily in 1–2 divided doses is recommended for chronic kidney disease with eGFR >30 mL/min per 1.73 m², with regular monitoring of electrolyte balance and serum creatinine. 5, 1

• No initial dose reduction is required for moderate renal impairment (CrCl 30–60 mL/min); standard dosing of 50–100 mg daily is appropriate. 6
• Monitor serum creatinine/eGFR and potassium within 1–2 weeks after initiating therapy or increasing doses, and then at least annually during maintenance therapy. 1
• A modest rise in serum creatinine of 0.1–0.3 mg/dL is expected and reflects hemodynamic alterations rather than true tubular injury; discontinuation is not required unless acute tubular necrosis is evident. 1

Severe Renal Impairment (CrCl <30 mL/min) and Hemodialysis

Losartan can be used in severe renal impairment and hemodialysis at standard doses (50–100 mg daily), as it is not removed during dialysis and has demonstrated safety in this population. 2, 6

• In patients with moderate to severe renal insufficiency (CrCl 10–29 mL/min), losartan 50–100 mg daily reduced blood pressure by an average of 14.1/10.6 mmHg at 12 weeks with good tolerability. 6
• In hemodialysis patients, losartan 50–100 mg daily achieved even greater reductions (22.7/18.0 mmHg at 12 weeks) and was well tolerated. 6
• Losartan and its active metabolite E-3174 are not removed during hemodialysis, so no supplemental dosing is required. 2
• Hyperkalemia (>6 mEq/L) requiring discontinuation occurred in only 1 of 112 patients with renal impairment in clinical trials. 6

Heart Failure with Reduced Ejection Fraction

For heart failure with reduced ejection fraction, the target dose is 100–150 mg daily; the HEAAL trial demonstrated that 150 mg daily was superior to 50 mg daily, achieving a 10% relative risk reduction in death or heart failure hospitalization. 1

• Start losartan at 50 mg once daily and titrate no more frequently than every 2 weeks to the target dose of 100–150 mg daily or the maximally tolerated dose. 1
• In heart failure patients with low baseline blood pressure, titrate weekly with small increments until reaching the target or highest tolerated dose, and monitor closely for symptomatic hypotension. 1
• Losartan is indicated for heart failure patients who cannot tolerate an ACE inhibitor, but should never be combined with an ACE inhibitor due to increased risk of hyperkalemia, syncope, and acute kidney injury. 1

Diabetic Kidney Disease

For diabetic nephropathy with albuminuria (UACR ≥300 mg/g), the target dose is 100 mg once daily as first-line therapy to slow progression of kidney disease. 1

• The RENAAL trial demonstrated that losartan 100 mg daily reduced the risk of the primary composite renal outcome by 20% (P=0.01) and lowered the risk of doubling serum creatinine by 28% (P=0.002) in patients with type 2 diabetes and macroalbuminuria. 1
• Losartan 25–100 mg daily in 1–2 divided doses is the KDOQI-recommended range for diabetic kidney disease, not exceeding 100 mg total daily dose. 1
• Check serum creatinine/eGFR and potassium within 1–2 weeks after initiating losartan therapy or increasing doses, especially in patients with diabetes or chronic kidney disease. 1
• Losartan can be continued as eGFR declines to <30 mL/min/1.73 m² for cardiovascular benefit, though closer monitoring is required. 1

Hepatic Impairment

In patients with mild-to-moderate hepatic impairment, start losartan at 25 mg once daily because plasma concentrations are approximately five-fold higher than in healthy individuals. 1

• No specific dosing recommendations exist for severe hepatic impairment; use with extreme caution and consider alternative agents. 1

Critical Safety Considerations

Losartan is absolutely contraindicated in pregnancy (all trimesters), with concurrent ACE inhibitors or direct renin inhibitors, in patients with a history of ARB-induced angioedema, and in severe bilateral renal-artery stenosis. 1

• Upon pregnancy detection, discontinue losartan immediately and switch to pregnancy-compatible antihypertensives such as methyldopa, labetalol, or extended-release nifedipine. 1
• Never combine losartan with ACE inhibitors or aliskiren; dual RAAS blockade increases the risk of hyperkalemia, syncope, and acute kidney injury by 2–3-fold without added cardiovascular benefit. 1
• Monitor serum potassium closely when losartan is combined with potassium-sparing diuretics, potassium supplements, or in patients with chronic kidney disease or diabetes. 1

Common Pitfalls to Avoid

• Do not underdose losartan; less than 25% of patients are ever titrated to target doses in clinical practice, yet higher doses provide greater benefits than lower doses. 1
• Do not delay treatment intensification; if blood pressure remains ≥140/90 mmHg on losartan 100 mg daily after 4–8 weeks, add a second agent rather than waiting longer. 1, 3
• Do not assume treatment failure without first confirming medication adherence, as non-adherence is the most common cause of apparent treatment resistance. 1, 3
• Do not stop losartan prematurely for mild hyperkalemia; implement potassium-lowering strategies (dietary restriction, diuretics, potassium binders) before discontinuing the medication. 1